Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas

Endocrine Journal

Volumn 56, Issue 4, 2009, Pages 579-584

  Tateno, Toru ^a   Kato, Masako ^a   Tani, Yuji ^a   Oyama, Kenichi ^b   Yamada, Shozo ^b   Hirata, Yukio ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b TORANOMON HOSPITAL   (Japan)

Author keywords

Cushing's disease; D2R; Non functioning pituitary tumor; Real time RT PCR; Silent corticotroph adenoma; SSTR

Indexed keywords

DOPAMINE 2 RECEPTOR; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5;

ACTH SECRETING ADENOMA; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CUSHING DISEASE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; NONFUNCTIONING PITUITARY ADENOMA; RECEPTOR GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEADY STATE;

ACTH-SECRETING PITUITARY ADENOMA; ADENOMA; ADRENOCORTICOTROPIC HORMONE; HUMANS; PITUITARY ACTH HYPERSECRETION; PITUITARY NEOPLASMS; RECEPTORS, DOPAMINE D2; RECEPTORS, SOMATOSTATIN;

EID: 68449089018     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K08E-186     Document Type: Article

References (28)

1. Orth DN (1995) Cushing's syndrome. N Engl J Med 332:791-803
2. Tateno T, Izumiyama H, Doi M, Yoshimoto T, Shichiri M, Inoshita N, Oyama K, Yamada S, Hirata Y (2007) differential gene expression in ACTH -secreting and non-functioning pituitary tumors. Eur J Endocrinol 157:717-724
3. Lamberts SW, Oosterom R, Neufeld M, del Pozo E (1985) The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients. J Clin Endocrinol Metab 60:1161-1165 (Pubitemid 15064776)
4. Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I, Lombardi G (2001) Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 86:2779-2786 (Pubitemid 32545739)
5. Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, James RA, McConnell M, Roberts GA, Scanlon MF, Stewart PM, Teasdale E, Turner HE, Wass JA, Wardlaw JM (2002) Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 87:4554-4563
6. Oshino S, Saitoh Y, Kasayama S, Arita N, Ohnishi T, Kohara H, Izumoto S, Yoshimine T (2006) Short-term preoperative octreotide treatment of GH-secreting pituitary adenoma: predictors of tumor shrinkage. Endocr J 53:125-132
7. Kennedy AL, Sheridan B, Montgomery DA (1978) ACTH and cortisol response to bromocriptine, and results of long-term therapy, in cushing's disease. Acta Endocrinol (Copenh) 89:461-468 (Pubitemid 9047822)
8. Boscaro M, Benato M, Mantero F (1983) Effect of bromocriptine in pituitary-dependent cushing's syndrome. Clin Endocrinol (Oxf) 19:485-491
9. Taboada GF, Luque RM, Neto LV, Machado Ede O, Sbaffi BC, Domingues RC, Marcondes JB, Chimelli LM, Fontes R, Niemeyer P, de Carvalho DP, Kineman RD, Gadelha MR (2008) Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. Eur J Endocrinol 158:295-303
10. Liebow C, Reilly C, Serrano M, Schally AV (1989) somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. Proc Natl Acad Sci U S A 86:2003-2007 (Pubitemid 19087056)
11. Buscail L, Delesque N, Esteve JP, Saint-Laurent N, Prats H, Clerc P, Robberecht P, Bell GI, Liebow C, Schally AV, et al. (1994) Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc Natl Acad Sci U S A 91:2315-2319 (Pubitemid 24092094)
12. Zatelli MC, Piccin D, Bottoni A, Ambrosio MR, Margutti A, Padovani R, Scanarini M, Taylor JE, Culler MD, Cavazzini L, degli Uberti EC (2004) Evidence for differential effects of selective somatostatin receptor subtype agonists on alpha-subunit and chromogranin a secretion and on cell viability in human nonfunctioning pituitary adenomas in vitro. J Clin Endocrinol Metab 89:5181-5188
13. Gruszka A, Kunert-Radek J, Radek A, Pisarek H, Taylor J, Dong JZ, Culler MD, Pawlikowski M (2006) The effect of selective sst1, sst2, sst5 somatostatin receptors agonists, a somatostatin/dopamine (SST/DA) chimera and bromocriptine on the "clinically non-functioning" pituitary adenomas in vitro. Life Sci 78:689-693
14. Hofland LJ, van der Hoek J, Feelders R, van der Lely AJ, de Herder W, Lamberts SW (2005) Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects. J Endocrinol Invest 28:36-42
15. Batista DL, Zhang X, Gejman R, Ansell PJ, Zhou Y, Johnson SA, Swearingen B, Hedley-Whyte ET, Stratakis CA, Klibanski A (2006) The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab 91:4482-4488 (Pubitemid 44833427)
16. Hofland LJ, van der Hoek J, Feelders R, van Aken MO, van Koetsveld PM, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, de Herder WW, Beckers A, Lamberts SW (2005) The multi-ligand somatostatin analogue SOM230 inhibits ACTh secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 152:645-654 (Pubitemid 40575811)
17. Stalla GK, Brockmeier SJ, Renner U, Newton C, Buchfelder M, Stalla J, Muller OA (1994) Octreotide exerts different effects in vivo and in vitro in Cushing's disease. Eur J Endocrinol 130:125-131 (Pubitemid 24112380)
18. Cervia D, Nunn C, Fehlmann D, Langenegger D, Schuepbach E, Hoyer D (2003) Pharmacological characterisation of native somatostatin receptors in AtT-20 mouse tumour corticotrophs. Br J Pharmacol 139:109-121 (Pubitemid 36645314)
19. Ben-Shlomo A, Wawrowsky KA, Proekt I, Wolkenfeld NM, Ren SG, Taylor J, Culler MD, Melmed S (2005) somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of adrenocorticotropin secretion. J Biol Chem 280:24011-24021 (Pubitemid 40884889)
20. van der Hoek J, Waaijers M, van Koetsveld PM, Sprij-Mooij D, Feelders RA, Schmid HA, Schoeffter P, Hoyer D, Cervia D, Taylor JE, Culler MD, Lamberts SW, Hofland LJ (2005) Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. Am J Physiol Endocrinol Metab 289:e278-e287 (Pubitemid 41076629)
21. Silva AP, Schoeffter P, Weckbecker G, Bruns C, Schmid HA (2005) Regulation of CRH-induced secretion of ACTH and corticosterone by SOM230 in rats. Eur J Endocrinol 153:R7-R10 (Pubitemid 41410505)
22. Miller GM, Alexander JM, Bikkal HA, Katznelson L, Zervas NT, Klibanski A (1995) Somatostatin receptor subtype gene expression in pituitary adenomas. J Clin Endocrinol Metab 80:1386-1392
23. Park S, Kamegai J, Kineman RD (2003) Role of glucocorticoids in the regulation of pituitary somatostatin receptor subtype (sst1-sst5) mrna levels: evidence for direct and somatostatin-mediated effects. Neuroendocrinology 78:163-175 (Pubitemid 37188082)
24. Lamberts SW, Klijn JG, de Quijada M, Timmermans HA, Uitterlinden P, de Jong FH, Birkenhager JC (1980) The mechanism of the suppressive action of bromocriptine on adrenocorticotropin secretion in patients with Cushing's disease and Nelson's syndrome. J Clin Endocrinol Metab 51:307-311
25. Pivonello R, Ferone D, de Herder WW, Kros JM, De Caro ML, Arvigo M, Annunziato L, Lombardi G, Colao A, Hofland LJ, Lamberts SW (2004) Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab 89:2452-2462 (Pubitemid 38619889)
26. Miller JW, Crapo L (1993) The medical treatment of Cushing's syndrome. Endocr Rev 14:443-458
27. Invitti C, De Martin M, Danesi L, Cavagnini F (1995) Effect of injectable bromocriptine in patients with Cushing's disease. Exp Clin Endocrinol Diabetes 103:266-271
28. Bevan JS, Webster J, Burke CW, Scanlon MF (1992) Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 13:220-240